Horizon Therapeutics (NASDAQ:HZNP) is scheduled to announce its earnings results before the market opens on Wednesday, August 7th. Analysts expect the company to announce earnings of $0.39 per share for the quarter. Horizon Therapeutics has set its FY 2019 guidance at EPS.Investors interested in listening to the company’s conference call can do so using this link.
Horizon Therapeutics (NASDAQ:HZNP) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.20. The business had revenue of $280.00 million for the quarter, compared to analysts’ expectations of $238.35 million. Horizon Therapeutics had a return on equity of 33.57% and a net margin of 3.79%. The company’s revenue for the quarter was up 25.0% compared to the same quarter last year. During the same period last year, the firm earned $0.03 earnings per share. On average, analysts expect Horizon Therapeutics to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Shares of NASDAQ HZNP opened at $23.12 on Tuesday. The firm has a market capitalization of $4.56 billion, a PE ratio of 12.63, a P/E/G ratio of 1.42 and a beta of 0.88. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.68 and a current ratio of 1.74. Horizon Therapeutics has a 12-month low of $16.56 and a 12-month high of $29.44. The company has a fifty day moving average of $24.09.
Several analysts have recently issued reports on HZNP shares. Mizuho set a $27.00 price objective on Horizon Therapeutics and gave the company a “hold” rating in a research note on Wednesday, May 8th. TheStreet cut Horizon Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, June 10th. BidaskClub cut Horizon Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, July 26th. Finally, Citigroup upgraded Horizon Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the company from $21.00 to $32.00 in a research note on Wednesday, May 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $31.91.
In other Horizon Therapeutics news, insider Jeff Kent sold 11,140 shares of the firm’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $23.84, for a total value of $265,577.60. Following the sale, the insider now directly owns 127,115 shares in the company, valued at $3,030,421.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Vikram Karnani sold 13,111 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $25.02, for a total value of $328,037.22. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 27,871 shares of company stock worth $682,812. 4.10% of the stock is owned by insiders.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Further Reading: What is a balanced fund?
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.